Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.

MLA

Hoshi, Shu-Ling, et al. “Cost-Effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against Herpes Zoster and Post-Herpetic Neuralgia among Adults Aged 65 and over in Japan.” Vaccine, vol. 37, no. 27, June 2019, pp. 3588–97. EBSCOhost, https://doi.org/10.1016/j.vaccine.2019.05.006.

APA

Hoshi, S.-L., Seposo, X., Shono, A., Okubo, I., & Kondo, M. (2019). Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan. Vaccine, 37(27), 3588–3597. https://doi.org/10.1016/j.vaccine.2019.05.006

Chicago

Hoshi, Shu-Ling, Xerxes Seposo, Aiko Shono, Ichiro Okubo, and Masahide Kondo. 2019. “Cost-Effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against Herpes Zoster and Post-Herpetic Neuralgia among Adults Aged 65 and over in Japan.” Vaccine 37 (27): 3588–97. doi:10.1016/j.vaccine.2019.05.006.